This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many investors.

Pfizer Inc. (NYSE:PFE) is included among the 12 Best Dividend Stocks with Yields Above 4%. Pfizer Inc. (NYSE:PFE) is a‌ major ...

Pfizer Inc. is a global biopharmaceutical leader with a diversified product portfolio and significant scale, supported by ...

Pfizer Inc. remains attractive with strong fundamentals, cost control, an expanding market, and new drugs. Click here to read ...

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.

After its best day in nearly four years Tuesday, Pfizer stock gave an encore performance. Shares of the drugmaker closed u ...

This drop brings the stock's year-to-date decline to almost 45%. A key question now is how MRNA's performance compares to that of its competitors.

The trial tested the kinase inhibitor TUKYSA with first-line combination therapy for patients with human epidermal growth ...

Obesity is a growing problem that now has effective treatments. Pfizer has been eager to develop a strong position in this area. This acquisition gives Pfizer a viable obesity drug candidate. Pfizer's ...